Acarix (Acarix)

Business description

Acarix, a Swedish company, has developed the CE-marked CADScor to enable about half of the patients to be ruled out from further, expensive testing. Private sales in Germany have started. Full EU sales may start from 2019. US sales might start from 2021.

Stock data

Market cap.SEK217.8m
Last closeSEK9.46
High / Low (52 weeks)SEK22.3 / SEK7.9
Stock market listingOMX
Forecast net cash (SEKm)105.1
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual2.8(29.4)(53.4)
Relative *(2.3)(27.6)(54.6)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Achillion Pharmaceuticals Acorda Therapeutics
Actinium Pharmaceuticals Active Biotech
Acucela Addex Therapeutics
Adherium Adocia
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris AFT Pharmaceuticals
Agennix Akari Therapeutics
Alchemia Alexza Pharmaceuticals
Algeta Alimera Sciences
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Allium Medical Solutions Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Arix Bioscience
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Ascendis Pharma ASIT biotech
ASLAN Pharmaceuticals Astex Pharmaceuticals
Athersys Atossa Genetics
Avacta Group Avalanche Biotechnologies
AVEO Pharmaceuticals Avita Medical
Balda Basilea Pharmaceutica
Bavarian Nordic Bellus Health
Benitec Biopharma BioCryst Pharmaceuticals
BioInvent BioLight Life Sciences
BioLineRx BiondVax Pharmaceuticals
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
Bone Therapeutics Bonesupport
BrainStorm Cell Therapeutics BTG
C4X Discovery Holdings Can-Fite BioPharma
Cantargia Capstone Therapeutics
Carmat CASI Pharmaceuticals
Cell Therapy Celldex Therapeutics
Cellectis Cellular Biomedicine Group
Celyad Cerulean Pharma
Circadian Technologies Clal Biotechnology Industries
Clavis Pharma Cleveland BioLabs
Clinigen Group Clinuvel
CO.DON CollPlant Holdings
Consort Medical Corium International
Crescendo Crossject
CSL Curetis NV
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
Egalet Corporation EKF Diagnostics
Elbit Medical Ellex Medical Lasers
Emergent BioSolutions Endocyte
Epigenomics Erytech Pharma
Esperion Therapeutics Evotec
Exact Sciences Exelixis
EyeGate Pharmaceuticals Factor Therapeutics
Formycon Forward Pharma
Fresenius SE & Co. KGaA Futura Medical
Galapagos Galmed Pharmaceuticals
Genedrive Genfit
Genkyotex Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Heat Biologics Inc. Heidelberg Pharma
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunicum Immunodiagnostic Systems Holdings
Immunovia ImmuPharma
Immutep Imprimis Pharmaceuticals
Imugene Incyte Corporation
Infinity Pharmaceuticals InMed Pharmaceuticals
Innate Pharma Insmed
Intec Pharma International Stem Cell
Invion Ion Beam Applications
Ipsogen Iridex
Ironwood Pharmaceuticals Islet Sciences
Ixico Japan Tobacco
KaloBios Pharmaceuticals Kane Biotech
Karolinska Development Kazia Therapeutics
Keryx Biopharmaceuticals Kiadis Pharma
Laboratorios Farmacéuticos ROVI LCA-Vision
LeMaitre Vascular Lifeline Scientific
LifeWatch Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene MGC Pharmaceuticals
Midatech Pharma MISSION Therapeutics
Molecular Partners MolMed
Mologen Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Navidea Biopharmaceuticals
Nektar Therapeutics NeoStem
Neovacs NetScientific
NeuroVive Pharmaceutical Newron Pharmaceuticals
Nexstim NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novacyt NPS Pharmaceuticals
Nuevolution Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncology Venture
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onxeo Onyx Pharmaceuticals
Opexa Therapeutics OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Orgenesis
Oryzon Genomics Ossur
OvaScience OWL
Oxford BioMedica Pacific Edge
Paion Paladin Labs
Patheon PDL BioPharma
Pharmacyclics PharmaMar
Pharmaxis Pharming Group
Photocure Phylogica
Pixium Vision Pluristem Therapeutics
Prescient Therapeutics Probiodrug
ProMetic Life Sciences Prosensa
Proteome Sciences PsiOxus
QRxPharma Quantum Genomics
Quantum Pharmaceuticals Race Oncology
RedHill Biopharma Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
Rovi RXi Pharmaceuticals
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Shire
Sierra Oncology Silence Therapeutics
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals T‐cell cancer therapies
Targovax TearLab Corp
Tekmira Telix Pharmaceuticals
TESARO Theraclion
Therapix Biosciences Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Titan Pharmaceuticals Tonix Pharmaceuticals
Topotarget Touchstone Innovations
Transgene Trillium Therapeutics
Trimel Pharmaceuticals TruScreen Ltd
TxCell UCB
UDG Healthcare uniQure NV
Universal Biosensors VBI Vaccines
Vectura Verastem
Verisante Technology Vernalis
Verona Pharma Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
VolitionRx WaferGen Biosystems
Xbrane Biopharma Xencor
Zafgen Zealand Pharma
Ziopharm Oncology

Company news

Notice of Annual General Meeting in Acarix AB

Mon, 23 Apr 2018 07:52:30 GMT

Medtech specialist Acarix AB names Christian Lindholm as Interim CEO

Fri, 23 Feb 2018 09:00:00 GMT

Acarix AB to seek new CEO

Mon, 06 Nov 2017 13:41:15 GMT

Acarix publishes the annual report for 2017

Mon, 23 Apr 2018 06:00:00 GMT

Acarix AB (publ) to present at Vator Securities Unicorn Summit on 7 March 2017

Thu, 09 Feb 2017 06:56:15 GMT

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2015A 0.0 (15.4) (15.4) (114.00) N/A N/A
2016A 0.0 (26.8) (26.8) (183.01) N/A N/A
2017E 0.7 (24.6) (26.1) (105.40) N/A N/A
2018E 1.7 (39.3) (41.6) (172.88) N/A N/A

Last updated on 23/02/2018

Investment summary

Acarix has laid the groundwork in 2017 for sales development in 2018. The main subset of the key Dan-NICAD study was published in November 2017 and should boost medical awareness. With six sales to Sept 30, slower than expected, forecasts have been adjusted although these will be revised regularly. Good sales growth in Europe is still expected from 2019. A new CEO will be appointed in 2018, the current CEO leaves in February.

Last updated on 02/03/2018

Industry outlook

CADScore helps doctors to identify cardiac patients who probably require no further risky invasive clinical testing. German private healthcare insurance covers about 10% of people and is the immediate target. Major German and EU sales need public reimbursement possibly from late 2019. US marketing will require a US clinical study. However, with no US trial announced, our expected US launch date is moved to 2022 from 2021. The US runs over 3.8m tests per year. A Danish prospective study has been announced to boost data and improve credibility with opinion leaders.

Last updated on 02/03/2018

Key management

Dr Werner Braun, Chairman
Christian Lindholm, CFO
Claus Bo Vöge Christensen, COO and co-founder

Company address

World Trade Center
Skeppsgatan 19
Malmö
SE-211 11
Sweden